Showing results 1 to 1 of 1
Issue Date | Title | Journal Title |
---|---|---|
2023 | Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19-14) | LANCET GASTROENTEROLOGY & HEPATOLOGY |